Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses. Cole M, Anastasiou P, Lee C, Yu X, deCastro A, Roelink J, Moore C, Mugarza E, Jones M, Valand K, Rana S, Colliver E, Angelova M, Enfield K, Magness A, Mullokandov A, Kelly G, Gruijl T, Molina-Arcas M, Swanton C, Downward J, van Maldegem F. Science Advances. 2024 Nov;10(44).
A Single-Arm Trial of Neoadjuvant Ipilimumab Plus Nivolumab With ChemoRadiotherapy in Patients With Resectable and Borderline Resectable Lung Cancer: The INCREASE Study. Bahce I, Dickhoff C, Schneiders FL, Veltman, JL, Heineman DJ, Hashemi SMS, Vrijmoet AB, Houda I, Ulas EB, Bakker J, van de Ven P, Bouwhuis N, Meijboom LJ, Oprea-Lager DE, van Maldegem F, Fransen MF, de Gruijl TD, Radonic T, Senan S. Journal for ImmunoTherapy of Cancer 2024 Sep 30;12(9).
Imaging mass cytometry in preclinical studies of lung cancer. F. van Maldegem Book chapter in “Revealing Uncharted Biology With Single Cell Multiplex Proteomic Technologies”, Elsevier, edited by W. Fantl. 2024 Jun 25
Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers. Mugarza E*, van Maldegem F*, Boumelha J*, Moore C, Rana S, Sopena ML, East P, Ambler R, Anastasiou P, Clavijo PR, Valand K, Cole M, Molina-Arcas M, Downward J. Science Advances, 2022 July 22;8. doi: 10.1126/sciadv.abm8780
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. Van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, Colliver E, Enfield K, Bah N, Tsang VSK, Mugarza E, Moore C, Hobson P, Levi D, Molina-Arcas M, Swanton C, Downward J. Nature Communications. 2021 Oct 8;12.